Printer Friendly

SYN X finalizes Alzheimer's clinical agreement with Ortho-Clinical Diagnostics.

SYN X Pharma Inc. (TSX: SYY) today announced that the Company has finalized an agreement with Ortho- Clinical Diagnostics, Inc. ("Ortho"), a Johnson & Johnson company, regarding a pivotal clinical trial for the first in vitro diagnostic test kit for Alzheimer's Disease (AD).

The AD technology for human in vitro diagnostic applications using glutamine synthetase as a marker was exclusively licensed to Ortho last October. This new agreement provides financial support to SYN X to complete an ongoing clinical trial, which may be submitted to the US FDA for approval.

Alzheimer's disease is a neuro-degenerative disease that results in progressive cognitive and memory impairment leading to terminal dementia. In 2001, an estimated 12 million people worldwide suffer from Alzheimer's disease. This number is expected to grow to approximately 22 million people worldwide by 2025.

About SYN X Pharma Inc.

SYN X is a research driven point-of-care diagnostic company dedicated to delivering innovative and quality products to its customers, and value to its shareholders. The company leverages its proven Proteomics Discovery Platform(TM) to rapidly discover and develop innovative diagnostic products to detect disease in its earliest stages, facilitating more effective treatments. The company's rich pipeline of products focuses on unmet medical needs in diabetes, cardiovascular and central nervous system (CNS) diseases. For further information, please visit our company website

CONTACT: Eugene Bortoluzzi, Executive Vice-President, Business Development & CFO, Tel: (416) 798-3445, Fax: (416) 798-3447, e-mail:
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Aug 28, 2003
Previous Article:IMI signs collaborative research agreement with AtheroGenics; International study includes 180 cardiac centers worldwide.
Next Article:Microbix Issues Third Quarter 2003 Results; Positive cash flow and progress on vaccine technology reported.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters